Foundry Partners, LLC Sage Therapeutics, Inc. Transaction History

Foundry Partners, LLC

  • $1.95 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 30, 2023
SELL
$32.2 - $43.61 $118,367 - $160,310
-3,676 Reduced 7.23%
47,180 $1.8 Million
Q3 2022

Oct 21, 2022
BUY
$32.28 - $43.27 $266,761 - $357,583
8,264 Added 19.4%
50,856 $1.99 Million
Q2 2022

Jul 28, 2022
BUY
$27.52 - $37.99 $1.17 Million - $1.62 Million
42,592 New
42,592 $1.38 Million

Others Institutions Holding SAGE

# of Institutions
198
Shares Held
46.5M
Call Options Held
402K
Put Options Held
209K
View Full List

About Sage Therapeutics, Inc.

SAGE Quotes by TradingView
  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Foundry Partners, LLC Portfolio

Follow Foundry Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Foundry Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Foundry Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email